Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281918
Status:
COMPLETED
Last Update Posted:
2013-09-19
First Post:
2006-01-24
Brief Title:
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
Phase III Trial of Combined Immunochemotherapy With Fludarabine Cyclophosphamide and Rituximab FCR Versus Chemotherapy With Fludarabine and Cyclophosphamide FC Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLL-8
Brief Summary:
This randomized phase III trial is studying fludarabine cyclophosphamide and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ML17102 | None | None | None |
| GCLLSG-CLL-8 | None | None | None |
| EU-20560 | None | None | None |